MedTrace Logo

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC

NCT02394015 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2020-03-27

No results posted yet for this study

Summary

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.

Conditions

  • Ovarian Epithelial Cancer Recurrent

Interventions

DRUG

Trabectedin and Pegylated Liposomal Doxorubicin

Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014

Sponsors & Collaborators

  • PharmaMar

    collaborator INDUSTRY

  • Grupo Español de Investigación en Cáncer de Ovario

    lead OTHER

Principal Investigators

  • Laura Vidal, MD · H. Clinic, Barcelona

  • Jose M Del Campo, MD · H. Vall d'Hebron, Barcelona

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-06
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02394015 on ClinicalTrials.gov